Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling

Abstract The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated by immunomodulatory antibodies specific for immune checkpoints. Among them, the programmed death ligand-1 (PD-L1) is of particular interest as it is expressed not only on T-cells, but also o...

Full description

Bibliographic Details
Main Authors: Margherita Passariello, Anna Morena D’Alise, Annachiara Esposito, Cinzia Vetrei, Guendalina Froechlich, Elisa Scarselli, Alfredo Nicosia, Claudia De Lorenzo
Format: Article
Published: Nature Publishing Group 2019-09-01
Series:Scientific Reports
Online Access: